SCHEMBL4375092

SCHEMBL4375092

CC(C)(NC(=O)Nc1ccc2[nH]c(-c3cscn3)nc2c1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.52
METAP1 P53582 8/20 0.48
METAP2 P50579 5/20 0.48
TSHR P16473 2/20 0.48
KDM4E B2RXH2 2/20 0.48
NPC1 O15118 2/20 0.48
TP53 P04637 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
FKBP1A P62942 1/20 0.48
HIF1A Q16665 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4375043 0.96 EGLN1 (0.48) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL6102155 0.86 AR (0.51) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL4370090 0.86 AR (0.51) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL4368910 0.86 AR (0.51) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL11208569 0.81 METAP1 (0.55) METAP1METAP2TSHRKDM4ENPC1
SCHEMBL4371058 0.81 METAP1 (0.47) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL4369971 0.81 METAP1 (0.47) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL4369464 0.81 METAP1 (0.47) EGLN1METAP1METAP2TSHRKDM4E
SCHEMBL4367957 0.81 METAP1 (0.48) METAP1METAP2TSHRKDM4ENPC1
SCHEMBL4365319 0.81 METAP1 (0.48) METAP1METAP2TSHRKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622592-B2 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-11-24 US claimed
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. 2006-02-16 US claimed
US-7622592-B2 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-11-24 US disclosed
US-7622592-B2 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-11-24 US disclosed
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators AR, SHBG, BRCA1 EGLN1 1604/4885METAP1 3988/4885METAP2 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.